Efficacy Chart Efficacy results in both cohorts at baseline and at Week 4 following the dose of SPL026 with support therapy • Results...
We are a long way from psychedelic-assisted therapy being taught in American colleges and Universities. However, that doesn’t mean there are no psychedelic...
Cybin moves its lead program forward as it completes enrollment of its Phase 2 study of major depressive disorder. The post Cybin Completes Phase 2 Enrollment...
The import to Filament’s Metro Vancouver facility was conducted in collaboration with the Peruvian government and facilitated by Filament Health and...
–Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase...
Psilo Scientific, a subsidiary of Filament, will use the leaves to research neuropsychiatric applications. The post Filament Brings Coca Leaves to Canada...
This has been a busy quarter for the psychedelic industry, particularly Lucy Scientific Discovery Inc. The company has announced three acquisitions in...
Numinus is ceasing operating activities at Numinus Bioscience and consolidating certain of its clinic operations. The post Numinus Closes Bioscience Lab...
Numinus is ceasing operating activities at Numinus Bioscience and consolidating certain of its clinic operations. The post Numinus Closes Bioscience Lab...
Enveric Biosciences (NASDAQ: ENVB) announced that the United States Patent and Trademark Office issued U.S. Patent No. 11,752,130, titled “Carboxylated...